Menu Schließen
opterion_press-release

Opterion successfully secures EUR 8.4m Bridge Financing Round

  • Opterion Health AG has secured commitments to raise EUR 8.4m to fund its final preclinical activities to create a new standard in Peritoneal Dialysis (PD) and prepare for Phase I.
  • The capital round funded by a small group of professional private and institutional investors from Switzerland and Germany, was oversubscribed by over 40%.
  • The company is also relocating its offices to Muttenz (BL), becoming part of the life science ecosystem of the Basel area.

19 January 2021 – Opterion Health AG, a preclinical Swiss life science company, developing the first novel solution for peritoneal dialysis (PD) in the last two decades, today announced the successful agreement of a EUR 8.4m Bridge Financing Round. This amount was exclusively raised from a limited number of professional private and institutional investors based in Switzerland and Germany. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I.

Opterion was founded in 2012 by scientist Guido Grentzmann. In 2015, a small number of renowned life science investors joined Opterion and meanwhile the team consists of experienced scientists and life science entrepreneurs supported by leading nephrologists in Switzerland and Europe.

The company is developing a novel peritoneal dialysis (PD) solution, aiming to revolutionize the dialysis market. Animal studies have shown the superiority of the Opterion PD solution over the “gold standard” of the current market leader.

Guido Grentzmann, the founder and CEO/CSO of Opterion comments: “The PD market has not seen any significant innovation for over two decades. Hence, there is a high unmet medical need for a novel solution that not only offers better therapy outcomes, but also has the potential for reduced side effects, improved quality of life and higher survival rates of dialysis patients. Over 45% of dialysis patients suffer from diabetes, and an increasing number of patients no longer want to visit a clinic or a hospital for their therapy. This is especially true in times of pandemic, as we are currently experiencing. Therefore, our glucose-free PD solution is a much-needed innovation not only for the very large number of diabetic dialysis patients, but also for dialysis patients who want to improve their quality of life by having their therapy at home.”

Andreas Schmidt, CFO of Opterion adds: “Thanks to the very successful completion of our financing round – which was oversubscribed by more than 40% – Opterion is now in the position of being very comfortably financed for the next two years. This gives us the opportunity to execute our scientific as well as manufacturing plans and prepare for Phase I with full speed.”

Further to the successful closing of its Bridge Financing Round, Opterion also announced that it will relocate its offices to Muttenz (BL). That way, it will become part of the life science ecosystem in the Basel area.

 

For more information, please contact:
Beatrix Benz at media@opterion.com or +41 79 256 77 73

 

About Opterion Health
Opterion Health AG is a preclinical Swiss life science company headquartered in Sarnen, Switzerland. It was created by Guido Grentzmann and other renowned scientists and nephrologists. The company is focused to bring innovation to dialysis care and foster home dialysis to improve quality of life for patients as well as their loved ones and strives to increase the survival rates of people who suffer from end-stage renal disease (ESRD). Opterion Health AG

Stefan Wohlfeil

Board Member
Stefan Wohlfeil, MD, has over 35 years of experience in the Pharma and Biotech industry. Most recently he was Chief Medical Officer and Head of R&D at Vifor Pharma with responsibility for preclinical and clinical R&D, regulatory and medical affairs as well as drug safety. Prior to that he was Global Head Clinical Research & Pharmacology at Novartis and Bayer. He also has experience as founder and CEO of two start-up companies in the oncology area, one of which was based in Japan. Stefan started his career at Bayer Pharma, where he worked for over 20 years in discovery research and preclinical and clinical development in Germany, USA and Japan. Stefan holds a Medical Doctor’s degree from the University of Düsseldorf, Germany.

Andreas Schmidt

CFO / Board

Andreas Schmid has more than 25 years of experience in Finance in the Life Sciences. He worked as a Pharma Analyst at Merrill Lynch and also has experience in fund raising as well as business development.

During the span of his career Andreas was one of the highest-ranked dialysis and generic pharma analysts, with special expertise in European and CEE/emerging markets. His coverage universe included companies such as Fresenius/FMC (Germany), Gambro (Sweden), Stada (Germany) and Aspen (South Africa). Furthermore, he played a major part in the IPOs of Zentiva (Czech Republic) and Hikma (Jordan). Andreas has also been active as a speaker at various industry conferences, for example in New York, Frankfurt, but also in Warsaw and other Eastern European countries.

In addition, Andreas works as finance lecturer at the Hochschule Pforzheim and is a board member of the German shareholder association SdK.

Ricardo Cordero

Vice Chairman
Dr Ricardo Cordero, PhD, serves as Vice Chairman of Opterion Health since 2016. Ricardo has over 30 years of experience in the Financial Services Industry where he held various senior positions, for example as CEO of BZ Bank, Managing Partner at Reichmuth & Co Investmentfonds AG, Co-founder and Co-CEO at BWO Bank, etc. Further, he is a passionate and experienced private Swiss investor and holds various investments in the Life Science, Technology and high-end Consumer Goods industry.

David Ebsworth

Chairman
Dr David Ebsworth, PhD, has been Chairman of Opterion Health since December 2016. David has over 40 years of experience in the Pharma, Healthcare and Biotech industry. David is a past CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences and past global head of the Pharmaceutical Division of Bayer. He has chaired several private and public companies and has served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. David is currently Chairman of Verona Pharma and Actimed Therapeutics.

Guido Grentzmann

CEO / CSO / Board
Dr Guido Grenzmann, PhD, is the founder of Opterion Health and has more than 25 years of experience in Pharma R&D and Project Management. After academic work on bacterial and viral mechanisms of translational regulation, he became Group Leader Molecular Biology/Genomics at Pfizer and Director Biochemistry/GeneProfiling at Altana Pharma where he worked in Discovery of inflammation in respiratory diseases. In 2007 he founded PBS PharmaBioServices providing contract research and consulting mainly in inflammatory diseases, in multiple therapeutic domains. 2012, Guido founded Opterion, with the aim to develop a new PD solution, to decrease side-effects of this promising therapy.